News

Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
 
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.


Burrill & Company Adds to Its Alternative Equities Group

June 03, 2011


SAN FRANCISCO, CA — June 3, 2011 — Burrill & Company is pleased to announce that Mr. Darren N. Streiler has been appointed as Principal, Burrill Alternative Equities Group, reporting to Peter Fry, Head of the Burrill Alternative Equities Group. Darren’s role will be to assist in the engagement of clients for the Group and to help with analyzing, structuring and underwriting of transactions.

Mr. Streiler has over 13 years of investment experience and, prior to joining Burrill & Company, he worked as an analyst for the San Francisco-based firm of HighMark Capital Management Inc. He was part of a team responsible for two actively managed, fundamental funds. Prior to that appointment he worked as a healthcare investmentsconsultant for Caxton Associates LP and as a healthcare analyst for S.A.C. Capital Advisors, L.P.

He holds a BS – Finance, from Boston College and an MBA – Business Administration, from the University of California, Berkeley Haas School of Business.
About Alternative Equities Group

The Burrill Alternative Equities Group provides a Committed Equity Line of Credit (CELoC) and will commit principal capital to select healthcare and life sciences companies that can be drawn down at management’s discretion and thereby, offer a cost-effective means of raising equity capital with unparalleled levels of flexibility, control and security.

About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking, and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia.
Upcoming Burrill & Company Events

The 2nd Annual Burrill Pan-Asia Life Sciences Meeting
June 26, 2011. Washington, D.C.
http://www.burrillandco.com/pan_asia_2011/

The Burrill Personalized Medicine Meeting
October 3-4, 2011. Burlingame, CA
http://www.burrillandco.com/personalized_medicine_2011/

For more information
Peter Winter
Managing Director, Editorial
415-591-5474

Back to News list  
News Archive: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All